Gene therapy clinical trials worldwide to 2007—an update

Abstract

To date, over 1340 gene therapy clinical trials have been completed, are ongoing or have been approved worldwide. In 1997 we set up a database to bring together global information on gene therapy clinical trials as comprehensively as possible. The data are compiled and regularly updated from official agency sources, published literature, conference presentations and posters and from information kindly provided by investigators or trial sponsors themselves.This review updates our descriptive overview of the data in 2004 1, presenting our analysis of the clinical trials that, to the best of our knowledge, have been or are being performed worldwide. As of July 30 2007, we have stored entries on 1309 trials in 28 countries. We have analyzed the geographical distribution of trials, the disease indications (or other reasons) for trials, the proportions to which different vector types are used, and which genes have been transferred. Details of the analyses presented, and our interactive, searchable database can be found on The Journal of Gene Medicine Gene Therapy Clinical Trials Worldwide website at: http://www.wiley.co.uk/genmed/clinical. Copyright © 2007 John Wiley & Sons, Ltd.

Foamy virus vectors: The usefulness of a perfect parasite

“…10 Gammaretrovirus (GV) and lentivirus (LV), the bases for most retroviral vectors in clinical use now, belong to the OV. 11 FV have the principal genetic order of LTR (long terminal repeat), gag-pol-env-accessory genes-LTR, reverse transcription and integration into the host cell genome in common with OV. However, a closer look will reveal differences in almost any aspect of replication.…”

Hybrid vector including polyethylenimine and cationic lipid, DOTMA, for gene delivery

“…The gene delivery vector is categorized into viral and non-viral vectors. The viral vector is highly effective and has been used in clinical trials, although some severe adverse events were of great concern for its safety (Edelstein et al, 2007). On the other hand, non-viral vectors have safety advantages: much lower immunotoxicity, a clear structure, and easy modeling; therefore, much attention has been paid to non-viral vectors (Tang et al, 1997;Fillion et al, 1998).…”

Mc-hES, a novel plasmid carrying human endostatin gene, inhibits nasopharyngeal carcinoma growth

“…23 Standard plasmid vectors are composed of a transgene expression cassette and plasmid bacterial backbone (BB) DNA. In our study, we used the I-sceI site, a jc31 recombinase temperature-sensitive recognition, and a cutting site to exclude the plasmid BB and degrade the BB.…”